SCHEMBL24144642

SCHEMBL24144642

CN(C)SNCCc1cn(Cc2ccc(F)cc2)c2cc(-c3ccncc3)ccc12

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NR1D1 P20393 10/20 0.49
▸ NFATC1 O95644 1/20 0.46
▸ GSK3B P49841 1/20 0.46
▸ DYRK1A Q13627 1/20 0.46
▸ SERPINE1 P05121 1/20 0.42
▸ CYP19A1 P11511 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ ALOX12 P18054 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ HTR6 P50406 1/20 0.37
▸ HAT1 O14929 1/20 0.37
▸ EP300 Q09472 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24143294 0.90 NR1D1 (0.47) NR1D1GSK3BCYP19A1KDM4ELMNA
SCHEMBL24143945 0.89 NR1D1 (0.48) NR1D1NFATC1GSK3BDYRK1AHAT1
SCHEMBL24143919 0.87 NR1D1 (0.47) NR1D1DYRK1AALDH1A1LMNAHTR6
SCHEMBL24144664 0.86 NR1D1 (0.49) NR1D1CYP19A1KDM4EALDH1A1MAPT
SCHEMBL24143305 0.85 NR1D1 (0.47) NR1D1CYP19A1HTR6
SCHEMBL24143255 0.85 NR1D1 (0.47) NR1D1HTR6
SCHEMBL24144643 0.84 NR1D1 (0.71) NR1D1
SCHEMBL24144679 0.83 NR1D1 (0.49) NR1D1GSK3BHTR6HAT1EP300
SCHEMBL24143302 0.81 NR1D1 (0.48) NR1D1NFATC1GSK3BDYRK1A
SCHEMBL24143548 0.81 NFATC1 (0.50) NR1D1NFATC1GSK3BDYRK1ASERPINE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021263278-A1 REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS THE SCRIPPS RESEARCH INSTITUTE (US) 2021-12-30 — — WO disclosed
Send feedback